82 results about "Native protein" patented technology

The invention relates to the field of biological detection, in particular to a monoclonal antibody combination for detecting human IL-6 protein and application. The combination comprises monoclonal antibodies 3A10 and 2G1, and amino acid sequences of complementary determining regions of variable regions of light and heavy chains of the monoclonal antibodies 3A10 and 2G1 are respectively shown as SEQ ID NO.1-12. The invention defines a complete variable region sequence and a coding nucleotide sequence of the antibody. The combination specifically recognizes human IL-6 recombinant and natural proteins, and has no cross reaction with IL-11. A double-antibody sandwich ELISA kit constructed based on the combination takes 3A10 as a coating antibody and 2G1 as a labeled antibody, and has high sensitivity and high specificity. The problems that an existing reagent is insufficient in specificity and low in sensitivity are solved, a reliable core raw material is provided for IL-6 standardized detection, and the method is suitable for preparation of a kit, a test strip and an antibody chip.

A gene editing protein variant is capable of reducing a gene editing off-target rate. The variant is an unnatural protein with cis-cleavage activity, and the variant has reduced trans-cleavage activity as compared to a wild-type gene editing protein thereof. Furthermore, the variant is mutated at one or more of cleavage activity-related core amino acid sites of the wild-type gene editing protein selected from the following: a phenylalanine (F) site corresponding to the 1081st position of FnCas12a; and / or a lysine (K) site corresponding to the 1069th site of the FnCas12a. The variant can have cis-cleavage activity and reduced trans-cleavage activity. Moreover, the gene editing protein variant or a gene editing system having the gene editing protein variant can significantly reduce the gene editing off-target rate.

The present invention relates to a method for the treatment of a semimanufactured product made of leather or similar material. The method comprises the steps of: - providing the semimanufactured product to be treated; - preparing a treatment solution comprising a binder solution and silver in granules; - applying the treatment solution to at least one surface of said semimanufactured product to be treated. The binder solution comprises natural proteins in aqueous solution. The present invention also relates to an item produced from a semimanufactured product made of leather or similar material treated with the aforesaid method.

The invention provides a high-protein feed raw material and a preparation method thereof, and belongs to the field of protein feeds.The preparation method comprises the steps that animal-derived organs are selected, an animal-derived organ enzyme solution is obtained through a pretreatment means, and natural protein components in the animal-derived organ enzyme solution are reserved to serve as crude protein nutritional ingredients; step 2, adding a substrate and a methyl donor into the animal-derived visceral organ enzyme liquid, and generating guanidinoacetic acid and creatine through an enzymatic synthesis reaction to obtain a mixed liquid; and step 3, carrying out enzyme system inactivation, centrifugal filtration, drying and crushing on the mixed solution to obtain a finished product. According to the invention, guanidinoacetic acid and creatine are synthesized by in-situ catalysis of animal-derived visceral organ natural enzyme systems, and can be naturally fused with protein components, so that the problem of compatibility is avoided, and growth functional factors do not need to be added from an external source; natural enzyme systems of animal livers and kidneys are directly utilized, industrial enzymes do not need to be purchased, and the natural enzyme systems are more adaptive to a raw material system; protein, natural enzyme systems and mineral substances in the raw materials are synchronously utilized, so that one material has multiple purposes.

The invention discloses a lactoferrin gel carrier, a preparation method thereof and application of the lactoferrin gel carrier in an oral delivery system. The preparation method comprises the following steps: mixing a lactoferrin solution with transglutaminase, and reacting under mild conditions to form a gel network. According to the method, gel which is compact in structure and high in stability is formed through enzyme catalytic crosslinking, the mechanical strength and embedding capacity of the gel are remarkably enhanced, and the method is suitable for embedding multiple active ingredients (such as probiotics, polyphenol and vitamins) sensitive to heat, oxygen or shear force. The obtained gel carrier can effectively isolate oxygen, moisture and adverse processing environments, and the stability of embedded components in processing, storage and transportation is remarkably improved. The carrier can be slowly released in a gastrointestinal tract environment, and active ingredients are prevented from being degraded too early in gastric acid, so that the intestinal absorption rate and the bioavailability of the carrier are improved. The materials used in the invention are natural proteins, are safe and non-toxic, and accord with food and health care product application standards.

The present application belongs to the technical field of bioengineering, and particularly relates to a Claudin18.2 gene engineering antibody based on DNA immunization and a preparation method and application thereof. The Claudin18.2 gene engineering antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of the amino acid sequences shown in SEQ ID NO. 15-16; and the light chain variable region comprises the amino acid sequences shown in SEQ ID NO. 19-20. The Claudin18.2 gene engineering antibody is obtained by immunizing Balb / c mice with full-length plasmid DNA and full-length plasmid DNA+extracellular segment polypeptide as immunogens respectively, obtaining plasma cells capable of secreting specific antibodies against Claudin18.2, and then preparing specific mouse-derived gene engineering antibodies through single-cell optical guidance technology and genetic engineering technology. The gene engineering antibodies have high titer and strong specificity, and have specific recognition ability for natural protein Claudin18.2.

The application provides a kind of liposome that can enhance organ targeting, preparation method and application, belongs to the field of biological medicine and nanotechnology.The application first proposes the strategy of actively regulating LNP organ targeting by pre-assembling specific protein crown in vitro, which breaks through the technical limitations of traditional passive formation of natural protein crown.Through selecting main lipids (CDO, CDA, EDM) with different head chemical structures, precise control of protein crown composition is realized.Furthermore, the method of the application is simple in process and mild in condition, only needs standard in vitro incubation steps, and has great clinical transformation potential.The pre-assembled protein crown method provided by the application significantly enhances the organ targeting efficiency of LNP: after pre-incubation of LNP1 with APOA1, the enrichment degree of spleen is increased by 2.8 times;after pre-incubation of LNP2 with VTN, the enrichment degree of lung is increased by 52%;after pre-incubation of LNP3 with APOE, the enrichment degree of liver is increased by 1.2 times.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The application provides a method and system capable of end-to-end protein design and analysis verification, and can generate protein or protein complex structure and sequence according to specific requirements, and the method comprises the following steps: performing loss calculation on the three-dimensional structure of the initialized protein sequence obtained through the structure prediction algorithm independently developed by the company based on confidence, stability, target correlation; continuously improving the designed protein sequence and structure based on the Markov chain Monte Carlo algorithm or gradient regression according to the obtained loss; and putting the designed protein structure into a sequence design model to optimize the side chain, and obtaining the optimal candidate protein through screening. The method can train the model to be specific and automatic for protein design, and can generate a new artificial protein which is completely different from natural protein in structure and sequence.

The invention discloses a hydrogel composite scaffold as well as a preparation method and application thereof. The hydrogel composite scaffold comprises a hydrogel matrix and drug-loaded microspheres loaded on the hydrogel matrix, the hydrogel matrix is grafted with a photosensitive group; the drug-loaded microsphere comprises a microsphere matrix and a drug loaded on the microsphere matrix; the hydrogel matrix and the microsphere matrix respectively and independently comprise natural protein and derivatives thereof; the natural protein and the derivative thereof comprise at least one of silk fibroin, sericin, collagen or gelatin. According to the invention, the natural protein and the derivative thereof are grafted and modified by adopting a photosensitive group, so that the injectable property can be realized, and the formed hydrogel matrix has good biological activity, can promote adhesion and proliferation of cells, and is combined with the drug-loaded microspheres to realize controlled release of drugs and promote regeneration and repair of damaged tissues. The hydrogel composite scaffold can be widely applied to preparation of biomedical materials, in particular to preparation of cartilage repair materials.

The invention provides an outdoor wool trouser fabric and a preparation method thereof, and the outdoor wool trouser fabric comprises a first protection layer which is arranged on the outermost side of the fabric and is used for providing wear-resistant protection and an external barrier; the second elastic supporting layer is arranged below the first protective layer, is interwoven and connected with the first protective layer and is used for providing dimensional elasticity and deformation support of the fabric; according to the invention, a full-link color spinning mode is constructed by adopting the first stock solution color filaments and the wool blended color spun yarns, and a low-temperature setting process at 130-140 DEG C is matched, so that a high-temperature and high-pressure environment at 130 DEG C or above in a traditional embryo dyeing process is completely avoided. The whole-process low-temperature steady-state processing mode effectively protects the natural protein structure of the wool fiber from being damaged by thermal denaturation, so that the original soft and glutinous hand feeling and biological activity of the wool are kept. In combination with the physical smoothing effect of oxidation desquamation treatment on fiber scales, the common needling feeling of the wool fabric is eliminated from the source, and the physiological comfort degree of close-fitting wearing is remarkably improved.

The invention discloses a recombinant duck plague virus protein combination, a subunit vaccine as well as a preparation method and application of the subunit vaccine, and belongs to the technical field of vaccine preparation. According to the technical scheme, the recombinant duck plague virus protein combination comprises recombinant gE protein and recombinant gI protein; the amino acid sequence of the recombinant gE protein is as shown in SEQ ID NO: 10, and the amino acid sequence of the recombinant gI protein is as shown in SEQ ID NO: 13. The nucleotide sequence of the nucleic acid molecule for coding the recombinant gE protein is as shown in SEQ ID NO: 12; the nucleotide sequence of the nucleic acid molecule for coding the recombinant gI protein is as shown in SEQ ID NO: 15. The duck plague subunit vaccine provided by the invention adopts gE and gI co-expression, only contains part of antigens of DPV, does not contain genetic materials, does not have toxin expelling and dispersing risks, is good in safety, can enable the spatial conformation of gE protein to be close to that of natural protein by co-expression of gE and gI, can realize 10 / 10 protection of challenge, has the total protein expression amount of about 4000 [mu] g / ml, and can be used for preparing a vaccine for the duck plague. The culture medium can be diluted by 40 times for seedling production, so that the production cost is greatly reduced.

The invention discloses an oligomeric protein de novo design method and system, terminal equipment and a computer readable storage medium. The method comprises the steps that functional characteristics of target protein are acquired, and a first design rule is determined based on the functional characteristics; based on the first design rule, extracting a first protein sequence and a second protein sequence from a natural protein database, and determining a second design rule; generating a candidate mutation sequence library according to the first design rule and the second design rule; performing structure prediction and stability calculation on the sequences in the candidate mutation sequence library, and screening out optimized sequences meeting preset requirements; performing functional characteristic simulation verification on the optimized sequence, and if the verification is passed, outputting a final target protein sequence; otherwise, the verification result is fed back to the protein sequence optimization model for iterative optimization design. The problem that the efficiency is low when the oligomeric protein is designed is solved, and the effect of efficiently designing the oligomeric protein from the beginning is achieved.

The invention relates to a wet spinning preparation process of protein modified polyacrylonitrile fibers, and relates to the field of wet spinning preparation processes, the wet spinning preparation process comprises the following steps: S1, heating and softening a spinning stock solution, dropwise adding a protein solution, and fully dissolving to obtain a clear and transparent protein modified spinning solution; s2, the protein modified spinning solution is sequentially subjected to filtering, defoaming, spinning, coagulating bath and drafting, and then the protein modified polyacrylonitrile fiber is obtained; the spinning stock solution is an acrylonitrile-methyl acrylate-itaconic acid ternary copolymerized stock solution. The acrylonitrile-methyl acrylate-itaconic acid ternary copolymerized stock solution is adopted as a spinning matrix, the compatibility with natural protein is improved by introducing a polar group, and the protein is uniformly dispersed at a molecular level in cooperation with a mode of dropwise adding the protein solution after heating and softening, so that the protein agglomeration phenomenon is remarkably reduced, and the uniformity of the internal structure of the fiber is improved.

Disclosed herein are a method, composition, and a kit for tagging a protein with a biorthogonal tag that may be used for various applications. Using a multi-step approach, native proteins may be labelled through an N-terminal amino acid reacting with a pyridine-2-carbaldehyde linker, which subsequently then reacts with an azide-functionalized tag, yielding a tagged protein. The tagged protein then can be used for nanopore translocation and proteomic assay studies.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

The invention discloses a preparation method of ultrasonic-heat treatment synergistically modified flaxseed protein and application of the flaxseed protein in ice cream. The method comprises the following steps: (1) degumming pretreatment of flaxseed cake meal; (2) flaxseed protein extraction; and (3) ultrasonic-heat treatment synergistic modification. The synergistic effect of ultrasonic and heat treatment can destroy the compact structure of flaxseed protein and expose more hydrophilic groups and hydrophobic groups, so that the solubility of the protein is improved to 80% or above, the emulsifying activity index is improved by 40% or above compared with that of natural protein, and the emulsion is still stable after being stored at 4 DEG C for 30 days; when the modified flaxseed protein is applied to the ice cream, the expansion rate of the product can be increased by 15-20%, the melting rate can be reduced by 25% or above, the hardness is moderate, the taste is smooth, and meanwhile the nutritional additional value of the product is increased. According to the method, resource upgrading of the flaxseed cakes is realized, low-price byproducts are converted into high-added-value food ingredients, the industrial chain of flaxseeds is prolonged, and the comprehensive benefits of the industry are improved.

The present application relates to the technical field of central obesity related research and treatment, by constructing a central obesity mouse model, it is found that the up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance. A BDNF fusion polypeptide composed of TAT cell-penetrating peptide, flexible linker and BDNF mature peptide is designed and prepared, the fusion polypeptide has strong cell viability promoting effect at the cellular level, can effectively activate the BDNF signaling pathway and has better stability than natural BDNF protein; an anti-TrkB monoclonal antibody with high affinity and high titer is also prepared. In vivo experiments show that the BDNF fusion polypeptide and its combination with the anti-TrkB monoclonal antibody can effectively inhibit the weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate the TrkB signaling pathway, and the combination has better synergistic therapeutic effect, which provides a new direction and experimental basis for the treatment of central obesity.

This invention discloses monoclonal antibodies that recognize linear B-cell epitopes in the conserved extracellular domain of pseudorabies virus (PRV) gE protein and their applications. Using recombinant PRV gE protein extracellular domain protein as an immunogen, hybridoma cell lines were prepared. Combining dot blot and peptide scanning techniques, two monoclonal antibodies, 4E5D7 and 8F6B2, were screened to recognize the 69-93aa region of the conserved extracellular domain of the PRV gE protein. Both antibodies achieved a titer of 1:2048000 and specifically recognized the native PRV wild-type gE protein, showing no cross-reactivity with gE gene-deleted vaccines. The monoclonal antibodies of this invention fill the gap in detection reagents targeting the precise epitopes of the 69-81aa and 79-93aa extracellular domains of the PRV gE protein, thus improving the linear B-cell epitope map of the PRV gE protein. These monoclonal antibodies can be used for research on the pathogenesis of PRV and the development of specific detection reagents for PRV wild-type strains, possessing significant application value and translational prospects in basic scientific research, veterinary clinical testing, and animal disease prevention and control.

The invention provides a copper calcium phosphate nano-enzyme fibroin antibacterial dressing as well as a preparation method and application thereof, and belongs to the technical field of material preparation. CCP HNS nano-enzyme with ascorbic acid oxidase is prepared through a coprecipitation method, nano-enzyme particles with controllable morphology, stable structure and excellent catalytic performance are obtained by regulating and controlling the ratio of copper to calcium and reaction conditions, and then the nano-enzyme particles are uniformly loaded on a natural protein material silk fibroin (SF), so that the nano-enzyme is prepared. The calcium copper phosphate nano-enzyme fibroin antibacterial dressing is obtained; the copper calcium phosphate nano-enzyme fibroin antibacterial dressing has an excellent antibacterial effect, is relatively low in cytotoxicity, maintains good cell viability and shows good biocompatibility; the copper calcium phosphate nano-enzyme fibroin antibacterial dressing has obvious advantages in the aspects of infection control, inflammation relief and tissue regeneration, can greatly shorten the wound closing time, shows good healing promoting ability, and has good practicability.

The invention discloses a natural neutrophil apolipoprotein dimer and a preparation method thereof, and belongs to the technical field of biomolecule preparation and biomedical detection. The problems that the recombinant protein dimer prepared by a genetic engineering recombination technology is low in yield, the structure of the recombinant protein dimer is different from that of natural protein, so that the development of antibodies and the detection effect of related kits are influenced, a method for extracting the recombinant protein dimer from peripheral blood is complicated, raw materials are not easy to obtain, and blood resources are wasted are solved. According to the preparation method disclosed by the invention, a leukocyte filter or a leukocyte layer generated in a component blood preparation process is taken as a raw material, a leukocyte lysis solution is adopted for lysis, and the obtained granulocyte lysis solution is combined with anion exchange and affinity chromatography methods to obtain the natural neutrophil apolipoprotein dimer. The preparation method can be used for preparing the natural neutrophil apolipoprotein dimer in batches, is simple and convenient to operate and high in protein yield, and can realize comprehensive utilization of blood resources and turn waste into wealth.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The invention relates to the technical field of biology, in particular to a monoclonal antibody SD6 based on theileria annulata SPAG protein and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody SD6 is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the monoclonal antibody SD6 is shown as SEQ ID No.2. The monoclonal antibody SD6 can recognize SPAG natural protein secreted by theileria annulata, the M / N value is as high as 21.2131, and the monoclonal antibody SD6 can be used for detecting the SPAG natural protein secreted by theileria annulata. The monoclonal antibody is used for preparing a detection kit or a test strip, and has important significance on diagnosis, prevention and control of bovine theileria annulata disease.

The application discloses a pig IZUMO2 eukaryotic protein and a preparation method and application of a monoclonal antibody of the pig IZUMO2 eukaryotic protein. The full-length sequence of pig IZUMO2 nucleotide CDS is verified, a research method for removing the transmembrane structure of the pig IZUMO2 nucleotide CDS and only expressing the extramembrane sequence of the pig IZUMO2 nucleotide CDS in eukaryotes is designed, and the IZUMO2 protein is expressed and secreted by CHO-K1 cells. The protein expressed by the method is close to natural protein, has biological activity and is simple to operate. The qPCR and ELISA tests verify that the IZUMO2 protein can reduce the expression of inflammatory factors in RAW264.7 cells induced by LPS, and has a certain anti-inflammatory capacity. It is found through experiments that the IZUMO2 protein can promote the capacitation of boar sperm, and it is proved that the protein can be applied to the preparation of a reagent for promoting the capacitation of boar sperm.

Disclosed in the present invention are a protein for inhibiting the conserved helix of TDP-43 and the use thereof. The protein contains an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. Further disclosed in the present invention are the use of the protein in the preparation of a drug for diagnosing, preventing and / or treating neurodegenerative diseases, and the use in the preparation of an inhibitor of a target protein containing the conserved helix of TDP-43 LCD. In the present invention, by means of using artificial intelligence-assisted protein design techniques, a high-affinity non-natural protein that precisely binds to the conserved helix of a TDP-43 protein is designed, which is used for inhibiting the participation of the conserved helix region in the formation of a β-sheet aggregation core, is mainly used in the treatment of diseases targeting the TDP-43 protein, such as amyotrophic lateral sclerosis, and is used as a research tool for TDP-43 protein phase separation experiments.

The present invention relates to method for purifying proteins naturally occurring in mammalian milk from aqueous protein solution using water-soluble silicate. The silicates form an insoluble precipitate of a silicate-protein complex from which the proteins can be isolated.

This invention discloses a combination of *Haemaphysema contortus* antigen proteins and its application in the preparation of a protective subunit vaccine against *Haemaphysema contortus*, belonging to the field of veterinary vaccines. The subunit vaccine of this invention comprises galactose and fucose-modified antigen proteins MEP1, MEP3, MEP4, PEP2, and CP1. The fucose modification includes proximal and distal α1,3-fucose modification. The antigen proteins in this subunit vaccine are closer to the natural proteins in terms of N-glycosylation modification, and can induce protective antibodies in goats after mixed immunization, significantly reducing the number of *Haemaphysema contortus* parasites and the number of eggs laid by the parasites. The subunit vaccine of this invention can be used to prepare drugs for the prevention and treatment of *Haemaphysema contortus* disease. This invention lays the foundation for the development of *Haemaphysema contortus* subunit vaccines, provides an effective technical means for the prevention and treatment of this disease, and has significant application value and promising prospects for promotion.

The application discloses a plant-expressed varicella-zoster virus gB recombinant antigen and a preparation method, product and application thereof, and belongs to the technical field of plant molecular biology and vaccine engineering. The technical problems to be solved are that the existing VZV gB protein has low heterologous expression, poor stability and insufficient antigen activity; the existing VZV vaccine has high production cost, is difficult to popularize and has a single antigen with an immune escape risk; and the plant expression system is not mature in VZV gB antigen production, and lacks a complete preparation scheme and related products. The technical solution is that the natural VZV gB protein is modified, a furin protease cleavage site is knocked out, and a H527P mutation is introduced, related nucleic acid molecules, vectors and plant source cells are constructed, high-activity antigens are obtained through culture and purification, and the high-activity antigens are applied to the preparation of VZV drugs / vaccines, and have the advantages of low cost, high safety and strong immunogenicity.

This invention belongs to the fields of food biotechnology and food processing, and discloses a method, product, and application for regulating the allergenicity of soybean protein based on heat-induced proanthocyanidin covalent modification. This invention aims to solve the problem of unstable regulation of soybean protein allergenicity during heat processing, and provides a stable and differentiated method for reducing allergenicity. The core of the method lies in: under heat treatment conditions, proanthocyanidins simultaneously covalently modify soybean 7S and 11S globulins, achieving differentiated regulation of their allergenicity. Products using this method exhibit the following specific pattern of allergenicity: 7S globulin products are significantly lower than heat-treated products; 11S globulin products are lower than heat-treated products and natural proteins. This low-allergenicity pattern remains stable after in vitro simulation of adult gastrointestinal digestion. This invention provides a targeted, mild, and efficient allergen regulation strategy, and the resulting products can be used to develop low-allergenic foods, special medical purpose formula foods, and dietary supplements.